Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-trace').style.display = (document.getElementById('cakeErr67f2ca9b55595-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f2ca9b55595-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-code').style.display = (document.getElementById('cakeErr67f2ca9b55595-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-context').style.display = (document.getElementById('cakeErr67f2ca9b55595-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f2ca9b55595-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f2ca9b55595-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 31272,
		&#039;title&#039; =&gt; &#039;Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;
&lt;br /&gt;
The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Doha Declaration&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;
&lt;br /&gt;
The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Big weakness&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;
&lt;br /&gt;
The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;
&lt;br /&gt;
The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 May, 2016, http://www.thehindu.com/business/Industry/intellectual-property-rights-policy-may-hinder-drug-access/article8596830.ece?w=alauto&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4679340,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 31272,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Compulsory licence,Compulsory licences,Compulsory license,Access to Healthcare,Access to Medicines,Patented Medicines,patents,Intellectual Property Rights,IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;

India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;&lt;br /&gt;The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Doha Declaration&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;&lt;br /&gt;The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Big weakness&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;&lt;br /&gt;The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;&lt;br /&gt;The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;&lt;br /&gt;International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 31272,
	&#039;title&#039; =&gt; &#039;Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;
&lt;br /&gt;
The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Doha Declaration&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;
&lt;br /&gt;
The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Big weakness&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;
&lt;br /&gt;
The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;
&lt;br /&gt;
The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 May, 2016, http://www.thehindu.com/business/Industry/intellectual-property-rights-policy-may-hinder-drug-access/article8596830.ece?w=alauto&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4679340,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 31272
$metaTitle = &#039;LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;
$metaKeywords = &#039;Compulsory licence,Compulsory licences,Compulsory license,Access to Healthcare,Access to Medicines,Patented Medicines,patents,Intellectual Property Rights,IPRs&#039;
$metaDesc = &#039;
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;

India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;&lt;br /&gt;The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Doha Declaration&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;&lt;br /&gt;The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Big weakness&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;&lt;br /&gt;The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;&lt;br /&gt;The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;&lt;br /&gt;International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra | Im4change.org</title>
    <meta name="description" content="
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&rsquo;

India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>The policy fails to acknowledge that IP is a market-driven model&rsquo;<br /></em><br />India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.<br /><br />The policy left the country&rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.<br /><br /><em>Doha Declaration<br /></em><br />The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.<br /><br />The policy, while underlining the Government&rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&eacute;decins Sans Fronti&egrave;res (MSF).<br /><br /><em>Big weakness<br /></em><br />&ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&rdquo; she said.<br /><br />&ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&rdquo; Ms. Menghaney said.<br /><br />The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.<br /><br />The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.<br /><br />International drug companies have often complained about price controls and marketing curbs by India.<br /><br />&ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-trace').style.display = (document.getElementById('cakeErr67f2ca9b55595-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f2ca9b55595-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-code').style.display = (document.getElementById('cakeErr67f2ca9b55595-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-context').style.display = (document.getElementById('cakeErr67f2ca9b55595-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f2ca9b55595-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f2ca9b55595-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 31272,
		&#039;title&#039; =&gt; &#039;Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;
&lt;br /&gt;
The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Doha Declaration&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;
&lt;br /&gt;
The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Big weakness&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;
&lt;br /&gt;
The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;
&lt;br /&gt;
The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 May, 2016, http://www.thehindu.com/business/Industry/intellectual-property-rights-policy-may-hinder-drug-access/article8596830.ece?w=alauto&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4679340,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 31272,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Compulsory licence,Compulsory licences,Compulsory license,Access to Healthcare,Access to Medicines,Patented Medicines,patents,Intellectual Property Rights,IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;

India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;&lt;br /&gt;The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Doha Declaration&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;&lt;br /&gt;The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Big weakness&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;&lt;br /&gt;The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;&lt;br /&gt;The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;&lt;br /&gt;International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 31272,
	&#039;title&#039; =&gt; &#039;Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;
&lt;br /&gt;
The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Doha Declaration&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;
&lt;br /&gt;
The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Big weakness&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;
&lt;br /&gt;
The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;
&lt;br /&gt;
The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 May, 2016, http://www.thehindu.com/business/Industry/intellectual-property-rights-policy-may-hinder-drug-access/article8596830.ece?w=alauto&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4679340,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 31272
$metaTitle = &#039;LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;
$metaKeywords = &#039;Compulsory licence,Compulsory licences,Compulsory license,Access to Healthcare,Access to Medicines,Patented Medicines,patents,Intellectual Property Rights,IPRs&#039;
$metaDesc = &#039;
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;

India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;&lt;br /&gt;The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Doha Declaration&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;&lt;br /&gt;The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Big weakness&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;&lt;br /&gt;The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;&lt;br /&gt;The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;&lt;br /&gt;International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra | Im4change.org</title>
    <meta name="description" content="
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&rsquo;

India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>The policy fails to acknowledge that IP is a market-driven model&rsquo;<br /></em><br />India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.<br /><br />The policy left the country&rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.<br /><br /><em>Doha Declaration<br /></em><br />The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.<br /><br />The policy, while underlining the Government&rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&eacute;decins Sans Fronti&egrave;res (MSF).<br /><br /><em>Big weakness<br /></em><br />&ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&rdquo; she said.<br /><br />&ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&rdquo; Ms. Menghaney said.<br /><br />The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.<br /><br />The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.<br /><br />International drug companies have often complained about price controls and marketing curbs by India.<br /><br />&ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-trace').style.display = (document.getElementById('cakeErr67f2ca9b55595-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f2ca9b55595-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-code').style.display = (document.getElementById('cakeErr67f2ca9b55595-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f2ca9b55595-context').style.display = (document.getElementById('cakeErr67f2ca9b55595-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f2ca9b55595-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f2ca9b55595-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 31272,
		&#039;title&#039; =&gt; &#039;Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;
&lt;br /&gt;
The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Doha Declaration&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;
&lt;br /&gt;
The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Big weakness&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;
&lt;br /&gt;
The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;
&lt;br /&gt;
The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 May, 2016, http://www.thehindu.com/business/Industry/intellectual-property-rights-policy-may-hinder-drug-access/article8596830.ece?w=alauto&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4679340,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 31272,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Compulsory licence,Compulsory licences,Compulsory license,Access to Healthcare,Access to Medicines,Patented Medicines,patents,Intellectual Property Rights,IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;

India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;&lt;br /&gt;The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Doha Declaration&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;&lt;br /&gt;The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Big weakness&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;&lt;br /&gt;The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;&lt;br /&gt;The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;&lt;br /&gt;International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 31272,
	&#039;title&#039; =&gt; &#039;Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;
&lt;br /&gt;
The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Doha Declaration&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;
&lt;br /&gt;
The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Big weakness&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;
&lt;br /&gt;
The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;
&lt;br /&gt;
The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;
&lt;br /&gt;
International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 13 May, 2016, http://www.thehindu.com/business/Industry/intellectual-property-rights-policy-may-hinder-drug-access/article8596830.ece?w=alauto&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4679340,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 31272
$metaTitle = &#039;LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra&#039;
$metaKeywords = &#039;Compulsory licence,Compulsory licences,Compulsory license,Access to Healthcare,Access to Medicines,Patented Medicines,patents,Intellectual Property Rights,IPRs&#039;
$metaDesc = &#039;
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;

India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;The policy fails to acknowledge that IP is a market-driven model&amp;rsquo;&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;India&amp;rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &amp;ldquo;serious&amp;rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.&lt;br /&gt;&lt;br /&gt;The policy left the country&amp;rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Doha Declaration&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.&lt;br /&gt;&lt;br /&gt;The policy, while underlining the Government&amp;rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&amp;eacute;decins Sans Fronti&amp;egrave;res (MSF).&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Big weakness&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;&amp;ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&amp;rdquo; she said.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&amp;rdquo; Ms. Menghaney said.&lt;br /&gt;&lt;br /&gt;The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.&lt;br /&gt;&lt;br /&gt;The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp;amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.&lt;br /&gt;&lt;br /&gt;International drug companies have often complained about price controls and marketing curbs by India.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&amp;rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra | Im4change.org</title>
    <meta name="description" content="
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&rsquo;

India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>The policy fails to acknowledge that IP is a market-driven model&rsquo;<br /></em><br />India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.<br /><br />The policy left the country&rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.<br /><br /><em>Doha Declaration<br /></em><br />The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.<br /><br />The policy, while underlining the Government&rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&eacute;decins Sans Fronti&egrave;res (MSF).<br /><br /><em>Big weakness<br /></em><br />&ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&rdquo; she said.<br /><br />&ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&rdquo; Ms. Menghaney said.<br /><br />The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.<br /><br />The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.<br /><br />International drug companies have often complained about price controls and marketing curbs by India.<br /><br />&ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 31272,
		'title' => 'Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu<br />
<br />
<em>The policy fails to acknowledge that IP is a market-driven model&rsquo;<br />
</em><br />
India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.<br />
<br />
The policy left the country&rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.<br />
<br />
<em>Doha Declaration<br />
</em><br />
The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.<br />
<br />
The policy, while underlining the Government&rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&eacute;decins Sans Fronti&egrave;res (MSF).<br />
<br />
<em>Big weakness<br />
</em><br />
&ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&rdquo; she said.<br />
<br />
&ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&rdquo; Ms. Menghaney said.<br />
<br />
The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.<br />
<br />
The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.<br />
<br />
International drug companies have often complained about price controls and marketing curbs by India.<br />
<br />
&ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. <br />
</div>',
		'credit_writer' => 'The Hindu, 13 May, 2016, http://www.thehindu.com/business/Industry/intellectual-property-rights-policy-may-hinder-drug-access/article8596830.ece?w=alauto',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4679340,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 31272,
	'metaTitle' => 'LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra',
	'metaKeywords' => 'Compulsory licence,Compulsory licences,Compulsory license,Access to Healthcare,Access to Medicines,Patented Medicines,patents,Intellectual Property Rights,IPRs',
	'metaDesc' => '
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&rsquo;

India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance...',
	'disp' => '<div align="justify">-The Hindu<br /><br /><em>The policy fails to acknowledge that IP is a market-driven model&rsquo;<br /></em><br />India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.<br /><br />The policy left the country&rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.<br /><br /><em>Doha Declaration<br /></em><br />The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.<br /><br />The policy, while underlining the Government&rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&eacute;decins Sans Fronti&egrave;res (MSF).<br /><br /><em>Big weakness<br /></em><br />&ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&rdquo; she said.<br /><br />&ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&rdquo; Ms. Menghaney said.<br /><br />The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.<br /><br />The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.<br /><br />International drug companies have often complained about price controls and marketing curbs by India.<br /><br />&ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. <br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 31272,
	'title' => 'Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu<br />
<br />
<em>The policy fails to acknowledge that IP is a market-driven model&rsquo;<br />
</em><br />
India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.<br />
<br />
The policy left the country&rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.<br />
<br />
<em>Doha Declaration<br />
</em><br />
The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.<br />
<br />
The policy, while underlining the Government&rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&eacute;decins Sans Fronti&egrave;res (MSF).<br />
<br />
<em>Big weakness<br />
</em><br />
&ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&rdquo; she said.<br />
<br />
&ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&rdquo; Ms. Menghaney said.<br />
<br />
The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.<br />
<br />
The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.<br />
<br />
International drug companies have often complained about price controls and marketing curbs by India.<br />
<br />
&ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. <br />
</div>',
	'credit_writer' => 'The Hindu, 13 May, 2016, http://www.thehindu.com/business/Industry/intellectual-property-rights-policy-may-hinder-drug-access/article8596830.ece?w=alauto',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'intellectual-property-rights-policy-may-hinder-drug-access-vidya-krishnan-and-puja-mehra-4679340',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4679340,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {},
		(int) 8 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 31272
$metaTitle = 'LATEST NEWS UPDATES | Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra'
$metaKeywords = 'Compulsory licence,Compulsory licences,Compulsory license,Access to Healthcare,Access to Medicines,Patented Medicines,patents,Intellectual Property Rights,IPRs'
$metaDesc = '
-The Hindu

The policy fails to acknowledge that IP is a market-driven model&rsquo;

India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance...'
$disp = '<div align="justify">-The Hindu<br /><br /><em>The policy fails to acknowledge that IP is a market-driven model&rsquo;<br /></em><br />India&rsquo;s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a &ldquo;serious&rdquo; hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts.<br /><br />The policy left the country&rsquo;s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation.<br /><br /><em>Doha Declaration<br /></em><br />The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner.<br /><br />The policy, while underlining the Government&rsquo;s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization M&eacute;decins Sans Fronti&egrave;res (MSF).<br /><br /><em>Big weakness<br /></em><br />&ldquo;With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,&rdquo; she said.<br /><br />&ldquo;It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,&rdquo; Ms. Menghaney said.<br /><br />The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs.<br /><br />The report came in the backdrop of increased pressure on the Department of Industrial Policy &amp; Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing.<br /><br />International drug companies have often complained about price controls and marketing curbs by India.<br /><br />&ldquo;Monopolies are loved by those who own monopolies because they give them commercial benefits,&rdquo; Union Finance Minister Arun Jaitley said after announcing the policy. <br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Intellectual Property Rights policy may hinder drug access -Vidya Krishnan and Puja Mehra

-The Hindu The policy fails to acknowledge that IP is a market-driven model’ India’s National Intellectual Property Rights (IPR) policy, unveiled on Friday, could pose a “serious” hurdle to allowing access to affordable drugs and the South Asian nation missed a chance to put in place a progressive policy, according to experts. The policy left the country’s patent laws intact and specifically did not open up Section 3(d) of the Patents Act, which sets the standard for what is considered an invention in India, for reinterpretation. Doha Declaration The government has also underlined its commitment to the Doha Declaration, which reaffirmed flexibilities (like Compulsory Licensing) given under TRIPS (Trade Related Aspects of Intellectual Property Rights) agreement to member states. Under compulsory licensing the government allows someone else to produce a patented product or process without the consent of the patent owner. The policy, while underlining the Government’s commitment to the Doha Declaration and TRIPS agreement, fails to explain how the vision will translate into reality, said Ms. Leena Menghaney, IP law expert and Access Campaigner at humanitarian aid organization Médecins Sans Frontières (MSF). Big weakness “With so much focus on turning all knowledge into patentable property, the big weakness in the document is that it is pitting innovation against access. There is no clarity in the section pertaining to commitment to Doha Declaration,” she said. “It is like saying that we reserve the right to give compulsory licences. But what is the point of reserving that right, if we are never actually going to issue licences because of pressure from the industry. Similarly, in the case of drugs for neglected disease, the IP policy fails to acknowledge that IP is a market-driven model. There will be serious impediments to access to drugs with this approach,” Ms. Menghaney said. The 301 report attacks section 3(d) of the Indian Patent Act, which has enabled the Indian government to establish stricter patentability standards for medicines -- allowing access to affordable generic drugs. The report came in the backdrop of increased pressure on the Department of Industrial Policy & Promotion (DIPP), the agency that administers IP laws and policy -- to ensure stringent IP enforcement, fast track examination of patent claims of its companies and a moratorium on compulsory licensing. International drug companies have often complained about price controls and marketing curbs by India. “Monopolies are loved by those who own monopolies because they give them commercial benefits,” Union Finance Minister Arun Jaitley said after announcing the policy.